5-(5-Methylpyridin-2-yl)pyrimidine | 341503-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(5-Methylpyridin-2-yl)pyrimidine
• CAS: 341503-03-5
• 化学式: C₁₀H₉N₃
• 分子量: 171.202
• InChiKey: PGAVIGGXUMBGLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-溴嘧啶 、 3-甲基吡啶 在 正丁基锂 、 N,N-二甲基乙醇胺 、 三丁基氯化锡 、 bis-triphenylphosphine-palladium(II) chloride 、 三苯基膦 作用下， 以 正己烷 、 四氢呋喃 、 xylene 为溶剂， 反应 14.5h， 以73%的产率得到5-(5-Methylpyridin-2-yl)pyrimidine
  参考文献：
  名称：

  Straightforward access to methyl-polyheterocycles from direct para-lithiation of 3-picoline

  摘要：

  Various heterocycles have been introduced on the 3-picoline nucleus via a regioselective BuLi-Me2N(CH2)(2)OLi (BuLi-LiDMAE) mediated para-lithiation. Useful methyl-polyheterocycles were efficiently prepared by a one-pot lithiation-stannylation-Stille coupling sequence. (C) 2001 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(01)00033-8

文献信息

• LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Umemura Eijirou

  公开号：US20100184746A1

  公开（公告）日：2010-07-22

  An objective of the present invention is to provide compounds of formula (I) or their pharmacologically acceptable salts or solvates wherein A represents aryl while R 1 represents a five- or six-membered monocyclic heterocyclic group, or A represents a four- to six-membered monocyclic heterocyclic group while R 1 represents aryl or a five- or six-membered monocyclic heterocyclic group; R 2 represents a hydrogen atom or C 1-6 alkyl; R 3 represents C 1-6 alkyl or C 3-6 cycloalkyl-C 1-4 alkyl; R 4 , R 5 , and R 6 represent a hydrogen atom; R 7 represents C 1-6 alkyl; and m is 1 to 3. The compounds are novel lincosamide derivatives that have a potent activity against resistant Streptococcus pneumoniae . Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目标是提供式（I）的化合物或其药理学上可接受的盐或溶剂，其中A代表芳基，而R1代表五元或六元单环杂环基，或A代表四至六元单环杂环基，而R1代表芳基或五元或六元单环杂环基；R2代表氢原子或C1-6烷基；R3代表C1-6烷基或C3-6环烷基-C1-4烷基；R4、R5和R6代表氢原子；R7代表C1-6烷基；m为1至3。这些化合物是新型的林可霉素衍生物，对耐药性肺炎链球菌具有强效活性。此外，这些化合物可用作抗微生物剂，对预防或治疗细菌感染性疾病有用。
• APPARATUS FOR SYNTHESIZING THE IMAGING AGENT 4-CHLORO-2-(1,1-DIMETHYLETHYL)-5-[[4-[[2-(FLUORO-[18F])ETHOXY]METHYL]PHENYL]METHOXY]-3(2H)-PYRIDAZINONE (FLUORPIRIDAZ [18F])
  申请人：Lantheus Medical Imaging, Inc.

  公开号：EP3653621A1

  公开（公告）日：2020-05-20

  An apparatus for synthesizing the imaging agent of the formula comprising a cassette as shown in Figure 17 with a linear arrangement of a plurality of stopcock manifolds arranged in the order: 1) luer connections to gas inlet and [18O]H2O recovery; 2) anion exchange cartridge - column eluting solution; 3) spike connection for acetonitrile; 4) empty syringe; 5) reservoir with solution of imaging agent precursor; 6) reaction vessel; 7) outlet to HPLC; 8) syringe with solution of a stabilizing agent; 9) inlet from HPLC; 10) ethanol reservoir; 11) syringe with solution of a stabilizing agent; 12) syringe with water; 13) final product vial; 14) empty syringe; and 15) reaction vessel and exhaust; further comprising tubing, an imaging agent synthesis module, wherein the apparatus is fluidically connected to the apparatus, and wherein the solution of a stabilizing agent comprises a solution comprising ascorbic acid or a salt thereof.

  一种合成式中成像剂的装置 包括一个如图 17 所示的盒体，盒体上直线排列着多个按顺序排列的截止阀歧管： 1）气体入口和[18O]H2O 回收的鲁尔接头； 2) 阴离子交换滤芯-柱洗脱液； 3) 用于乙腈的尖头连接； 4) 空注射器 5) 装有成像剂前体溶液的容器； 6) 反应容器 7) 连接 HPLC 的出口； 8) 装有稳定剂溶液的注射器； 9) 高效液相色谱仪的入口 10）乙醇储液器 11) 装有稳定剂溶液的注射器； 12) 装有水的注射器 13) 最终产品小瓶 14) 空注射器；以及 15) 反应容器和排气管； 进一步包括管道、成像剂合成模块，其中该装置与该设备流体连接，稳定剂溶液包括由抗坏血酸或其盐组成的溶液。
• US7867980B2
  申请人：——

  公开号：US7867980B2

  公开（公告）日：2011-01-11
• Straightforward access to methyl-polyheterocycles from direct para-lithiation of 3-picoline
  作者：Julien Mathieu、Philippe Gros、Yves Fort

  DOI：10.1016/s0040-4039(01)00033-8

  日期：2001.3

  Various heterocycles have been introduced on the 3-picoline nucleus via a regioselective BuLi-Me2N(CH2)(2)OLi (BuLi-LiDMAE) mediated para-lithiation. Useful methyl-polyheterocycles were efficiently prepared by a one-pot lithiation-stannylation-Stille coupling sequence. (C) 2001 Published by Elsevier Science Ltd.